Cargando...
Emerging drugs for head and neck cancer
INTRODUCTION: Despite improvements in treatment, survival rates of head and neck squamous cell carcinoma (HNSCC) are stagnant. The existing chemotherapeutic agents are non-selective and associated with toxicities. Combinations of the only the US FDA-approved epidermal growth factor receptor (EGFR)-t...
Gardado en:
| Publicado en: | Expert Opin Emerg Drugs |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5678969/ https://ncbi.nlm.nih.gov/pubmed/25826749 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14728214.2015.1031653 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|